ATE464909T1 - Humane anti-chemokinrezeptoren igm antikörper - Google Patents
Humane anti-chemokinrezeptoren igm antikörperInfo
- Publication number
- ATE464909T1 ATE464909T1 AT00978542T AT00978542T ATE464909T1 AT E464909 T1 ATE464909 T1 AT E464909T1 AT 00978542 T AT00978542 T AT 00978542T AT 00978542 T AT00978542 T AT 00978542T AT E464909 T1 ATE464909 T1 AT E464909T1
- Authority
- AT
- Austria
- Prior art keywords
- hiv
- receptors
- human anti
- chemokine receptors
- igm antibodies
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43969099A | 1999-11-15 | 1999-11-15 | |
US09/684,813 US6610834B1 (en) | 1998-11-18 | 2000-10-10 | Human IgM antibodies to chemokine receptors |
PCT/US2000/031051 WO2001035980A1 (en) | 1999-11-14 | 2000-11-14 | HUMAN IgM ANTIBODIES TO CHEMOKINE RECEPTORS |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE464909T1 true ATE464909T1 (de) | 2010-05-15 |
Family
ID=27032133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00978542T ATE464909T1 (de) | 1999-11-15 | 2000-11-14 | Humane anti-chemokinrezeptoren igm antikörper |
Country Status (8)
Country | Link |
---|---|
US (1) | US6610834B1 (de) |
EP (1) | EP1231930B1 (de) |
JP (1) | JP2003516940A (de) |
AT (1) | ATE464909T1 (de) |
AU (1) | AU1599601A (de) |
CA (1) | CA2389851A1 (de) |
DE (1) | DE60044259D1 (de) |
WO (1) | WO2001035980A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080118522A1 (en) * | 1998-11-18 | 2008-05-22 | Lobo Peter I | Naturally occuring IgM antibodies that bind lymphocytes |
US20030099645A1 (en) * | 2000-10-10 | 2003-05-29 | Lobo Peter Isaac | Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes |
WO2006059176A1 (en) * | 2004-12-01 | 2006-06-08 | Lobo Peter I | Naturally occuring igm antibodies that bind lymphocytes |
CA2563334A1 (en) * | 2004-04-16 | 2005-11-17 | Genentech, Inc. | Assay for antibodies |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
EP1993584B1 (de) | 2006-02-02 | 2012-05-30 | Allergan, Inc. | CXCR4-Hemmer-Therapie zur Verwendung bei der Behandlung von Augenerkrankungen |
MX2009001204A (es) | 2006-08-17 | 2009-02-11 | Hoffmann La Roche | Conjugado de un anticuerpo cointra ccr5 y un peptido antifusogenico. |
TW200817438A (en) * | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
BRPI0717512A2 (pt) | 2006-09-29 | 2013-11-19 | Hoffmann La Roche | Anticorpos contra ccr5 e usos dos mesmos |
CL2008000707A1 (es) * | 2007-03-13 | 2008-09-22 | Hoffmann La Roche | Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion. |
GB201002238D0 (en) | 2010-02-10 | 2010-03-31 | Affitech As | Antibodies |
WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
EP3835787A1 (de) * | 2016-02-16 | 2021-06-16 | CellTrend GmbH | Anti-cxc-chemokin-rezeptor-antikörper und c-x-c-chemokine zur prognose von akute graft-versus-host-erkrankungen |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8605316D0 (en) * | 1986-03-04 | 1986-04-09 | Royal Free Hosp School Med | Immunosuppression |
US5215913A (en) * | 1987-11-30 | 1993-06-01 | Roger Williams General Hospital | IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use |
US5606026A (en) * | 1988-03-25 | 1997-02-25 | The Institute For Human Genetics And Biochemistry | Natural human IgM antibodies immunoreactive with the Tat protein of HIV-1 |
ATE199392T1 (de) * | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
US5961976A (en) * | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
US5994515A (en) * | 1996-06-25 | 1999-11-30 | Trustees Of The University Of Pennsylvania | Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same |
WO1997049424A1 (en) | 1996-06-25 | 1997-12-31 | The Trustees Of The University Of Pennsylvania | Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same |
US6057102A (en) * | 1996-08-08 | 2000-05-02 | The Aaron Diamond Aids Research Center | HIV coreceptor mutants |
US6100387A (en) | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
JP2000229997A (ja) * | 1999-02-10 | 2000-08-22 | Nissui Pharm Co Ltd | 環状ペプチド及びエイズワクチン |
-
2000
- 2000-10-10 US US09/684,813 patent/US6610834B1/en not_active Expired - Fee Related
- 2000-11-14 AU AU15996/01A patent/AU1599601A/en not_active Abandoned
- 2000-11-14 CA CA002389851A patent/CA2389851A1/en not_active Abandoned
- 2000-11-14 EP EP00978542A patent/EP1231930B1/de not_active Expired - Lifetime
- 2000-11-14 JP JP2001537971A patent/JP2003516940A/ja active Pending
- 2000-11-14 WO PCT/US2000/031051 patent/WO2001035980A1/en active Application Filing
- 2000-11-14 DE DE60044259T patent/DE60044259D1/de not_active Expired - Lifetime
- 2000-11-14 AT AT00978542T patent/ATE464909T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1231930A1 (de) | 2002-08-21 |
WO2001035980A1 (en) | 2001-05-25 |
EP1231930B1 (de) | 2010-04-21 |
CA2389851A1 (en) | 2001-05-25 |
DE60044259D1 (de) | 2010-06-02 |
JP2003516940A (ja) | 2003-05-20 |
US6610834B1 (en) | 2003-08-26 |
EP1231930A4 (de) | 2005-07-27 |
AU1599601A (en) | 2001-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Melenotte et al. | Immune responses during COVID-19 infection | |
ATE464909T1 (de) | Humane anti-chemokinrezeptoren igm antikörper | |
Lopalco et al. | CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro | |
Clerici et al. | Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41 | |
Johansson et al. | NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients | |
Fouts et al. | Crosslinked HIV-1 envelope–CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques | |
Lidbury et al. | Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection | |
Pandrea et al. | Simian immunodeficiency virus SIVagm dynamics in African green monkeys | |
Kohler et al. | Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination | |
Klasse et al. | How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? | |
ATE397014T1 (de) | Hiv-peptide, antigene und impfstoffzusammensetzungen | |
Hosie et al. | A monoclonal antibody which blocks infection with feline immunodeficiency virus identifies a possible non-CD4 receptor | |
WO2001059457A3 (en) | Assay for detection of viral fusion inhibitors | |
Kulkarni et al. | Indian long-term non-progressors show broad ADCC responses with preferential recognition of V3 region of envelope and a region from Tat protein | |
Lohman et al. | Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay | |
Geiben-Lynn et al. | Noncytolytic inhibition of X4 virus by bulk CD8+ cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by β-chemokines | |
EA200300335A1 (ru) | Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич | |
Greczmiel et al. | LCMV‐specific CD4 T cell dependent polyclonal B‐cell activation upon persistent viral infection is short lived and extrafollicular | |
Motsoeneng et al. | Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination | |
Leinert et al. | Microbial translocation in simian immunodeficiency virus (SIV)‐infected rhesus monkeys (Macaca mulatta) | |
Locher et al. | Short Communication Antibody and Cellular Immune Responses in Breakthrough Infection Subjects after HIV Type 1 Glycoprotein 120 Vaccination | |
Lozano Reina et al. | Gag p27-specific B-and T-cell responses in Simian immunodeficiency virus SIVagm-infected African green monkeys | |
Liao et al. | Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains | |
Brown et al. | The conserved carboxy terminal region of HIV-1 gp120 is recognized by seronegative HIV-exposed people | |
Hirbod et al. | HIV-1 neutralizing activity is correlated with increased levels of chemokines in saliva of HIV-1-exposed uninfected individuals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |